BOSTON — OM1 has added 500,000 patients to its Neurology Specialty Network, bringing the total to more than 3 million and making it one of the largest neurology-focused real-world data resources available. The expansion is designed to enhance research and innovation across neurological conditions, including Alzheimer’s disease, multiple sclerosis, Parkinson’s disease, migraine, and amyotrophic lateral sclerosis (ALS).
The network integrates electronic health records and specialist notes, offering both structured and unstructured clinical data. OM1’s PremiOM™ datasets link this information with medical and pharmacy claims, curated outcomes, and AI-driven analytics to support faster, more detailed evidence generation for researchers and healthcare providers.
“Expanding our neurology network to more than 3 million patients represents a pivotal milestone in enabling better outcomes for neurology patients,” said Dr. Carl Marci, chief clinical officer and managing director of mental health and neuroscience at OM1. “By integrating deep clinical data and advanced AI, we’re equipping researchers and healthcare providers with powerful tools to uncover new insights into disease progression, treatment response, and more personalized care.”
The neurology network also connects with OM1’s Primary Care Network, covering more than 22 million patients, and its Mental Health Network, which includes 6 million patients. This linkage allows researchers to track the full patient journey from initial symptoms to diagnosis and ongoing treatment.
Neurological disorders are the leading cause of disability and the second leading cause of death globally, according to the World Health Organization, highlighting the need for high-quality real-world evidence to improve care and develop new therapies.
OM1 said the expanded network positions it to help life sciences and healthcare organizations accelerate discovery, advance precision medicine, and improve outcomes for patients with complex neurological conditions.
